GM Investment

GM Investment (often referred to as G&M Investment Group) is a private investment firm primarily known for its significant role as a major shareholder and strategic partner of GNI Group, a leading international pharmaceutical company listed on the Tokyo Stock Exchange. The firm focuses on the life sciences and healthcare sectors, providing capital and strategic guidance to companies developing innovative therapies, particularly in the fields of fibrosis, oncology, and inflammatory diseases. Through its association with GNI Group, GM Investment is indirectly involved in the commercialization of drugs like pirfenidone and the development of a robust pipeline of small molecule and biologic candidates. The company operates as a key vehicle for the founders and strategic investors of GNI Group to manage their interests and support long-term growth in the biotech industry.